8:30 Registration & Coffee

8:55 Chairman’s Welcome

9:00 Leading Through Technique – How To Speed Up Uptake And Your R&D

• Development strategies for bad soluble NCIs
• Pros and cons of different approaches to improve solubility and bioavailability
• Screening tools
• Scale-up
• Hot melt extrusion

Dr. Karl Werner
Associate Director Pharmaceutical Development, QP and Head of Production
Æterna Zentaris GmbH, Germany

9:40 Estimating Drug Solubility In The Gastrointestinal Tract

• Why estimate intra-lumenal solubility of drugs?
• Procedures for aspirating and measuring solubility in the gastrointestinal fluids
• Estimation of drug solubility in the stomach and the small intestine in the fasted and fed state
• Use of drug dissolution and solubility data in predicting plasma profiles

Dr. Maria Vertzoni
Research Fellow
National & Kapodistrian University of Athens, Greece

10:20 Refreshment Break & Networking

10:50 Implementing New Test Methods: Physiological Relevant In Vitro Testing

• Short introduction: gastrointestinal physiology (human vs. canine GI tract)
• In vitro tools used for testing bioperformance
• Example for physiological relevant in vitro testing: the TIM system
• Application examples of TIM in combination with in silico modeling

Susann Bellmann
Project Manager, TNO Quality of Life
Biosciences, The Netherlands

11:30 Silica carriers for improved solubility

• Appearance of Ordered Mesoporous Silica
• Physical characteristics
• Preparation
• Loading procedure
• In vitro – in vivo correlation
• Formulation and enhanced solubility

Hans Platteeuw
Chief Operating Officer
FORMAC Pharmaceuticals NV, Belgium

12:10 Networking Luncheon

13:40 Lipid Based Drug Delivery Systems To Enhance Oral Bioavailability Of NCEs

• Rational design of lipid-based formulation
• Impact of key formulation parameters on in vivo performance
• In vitro - in vivo assessment
• Case studies

Dr. Jean Cuiné
Fellow and Project Leader in Pharmaceutical and Analytical R&D
Novartis Pharma AG Switzerland

14:20 One Technology – Multiple Applications: Melt Processing For Tailored Product Characteristics

• The challenge: Poor solubility and tailored release profiles
• The concept: Solid dispersion / solid solutions
• The technology: Meltrex - melt extrusion
• The profile: evaluating solubility and drug release
• The case study: Kaletra® tablet
• Tailored release profiles

Dr. Jörg Breitenbach
Senior Director Drug Product Development, Head of SOLIQS
Abbott GmbH & Co. KG, Germany

15:00 Refreshment Break & Networking

15:30 Delivery Of Solid Oral Nanoparticulate Formulations To Enhance Drug Exposure

• Market situation
• Overview about current technologies
• Analytical characterization
• Stability aspects
• In-vivo aspects

Dr. Carsten Timpe
Fellow
Novartis Pharma AG, Switzerland

16:10 Nanosizing: A Tool To Increase The Bioavailability Of Poorly Water Soluble Drug Molecules

• Update on recent developments in the particle size reduction area
• Aspects that need to be considered during development
• Nanosizing in various stages of development
• Case studies

Dr. Jan Möschwitzer
Head Early Pharmaceutical Development
Solvay Pharmaceuticals B.V., The Netherlands

16:50 Inhalation Powder Products: Formulation Strategy For Poorly Soluble Compounds And Dissolution Testing

• Formulation of inhaled products
• Strategies to modify dissolution
• Dissolution testing of inhaled powder products

Dr. Jörg Schiewe
Principle Scientist
Boehringer Ingelheim Pharma GmbH & Co. KG, Germany

17:30 Closing Remarks Of The Chairman And End Of The Conference